%0 Journal Article
%T A Delphi consensus statement for the management of post-COVID interstitial lung disease.
%A Hadda V
%A Suri TM
%A Iyer H
%A Jain A
%A Mittal S
%A Madan K
%A Mohan A
%A Seith Bhalla A
%A Sindhwani G
%A Dutt N
%A Venkatnarayan K
%A Nath A
%A Dhooria S
%A Kumar R
%A Marwah V
%A Karmakar S
%A Chaudhry D
%A Ayub II
%A Dwivedi DP
%A Tiwari P
%A Koul P
%A Behera AK
%A Saxena P
%A Sengupta A
%A Mohapatra PR
%A Goyal A
%A Christopher DJ
%A Guleria R
%J Expert Rev Respir Med
%V 16
%N 9
%D 09 2022
%M 36154545
%F 4.3
%R 10.1080/17476348.2022.2128770
%X As millions of people worldwide recover from COVID-19, a substantial proportion continue to have persistent symptoms, pulmonary function abnormalities, and radiological findings suggestive of post-COVID interstitial lung disease (ILD). To date, there is limited scientific evidence on the management of post-COVID ILD, necessitating a consensus-based approach.<BR>A panel of experts in pulmonology and thoracic radiology was constituted. Key questions regarding the management of post-COVID ILD were identified. A search was performed on PubMed and EMBASE and updated till 1 March 2022. The relevant literature regarding the epidemiology, pathophysiology, diagnosis and treatment of post-COVID ILD was summarized. Subsequently, suggestions regarding the management of these patients were framed, and a consensus was obtained using the Delphi approach. Those suggestions which were approved by over 80% of the panelists were accepted. The final document was approved by all panel members.<BR>Dedicated facilities should be established for the care of patients with post-COVID ILD. Symptom screening, pulmonary function testing, and thoracic imaging have a role in the diagnosis. The pharmacologic and non-pharmacologic options for the management of post-COVID ILD are discussed. Further research into the pathophysiology and management of post-COVID ILD will improve our understanding of this condition.